|
1
|
Metra M and Teerlink JR: Heart failure.
Lancet. 390:1981–1995. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burchfield JS, Xie M and Hill JA:
Pathological ventricular remodeling: Mechanisms: Part 1 of 2.
Circulation. 128:388–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Opie LH, Commerford PJ, Gersh BJ and
Pfeffer MA: Controversies in ventricular remodelling. Lancet.
367:356–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drazner MH: The progression of
hypertensive heart disease. Circulation. 123:327–334. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Houser SR, Margulies KB, Murphy AM,
Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin
JD, Sussman MA, et al: Animal models of heart failure: A scientific
statement from the american heart association. Circ Res.
111:131–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimizu I and Minamino T: Physiological
and pathological cardiac hypertrophy. J Mol Cell Cardiol.
97:245–262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heineke J and Molkentin JD: Regulation of
cardiac hypertrophy by intracellular signalling pathways. Nature
reviews. Nat Rev Mol Cell Biol. 7:589–600. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tham YK, Bernardo BC, Ooi JY, Weeks KL and
McMullen JR: Pathophysiology of cardiac hypertrophy and heart
failure: Signaling pathways and novel therapeutic targets. Arch
Toxicol. 89:1401–1438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Panossian A and Wikman G: Pharmacology of
schisandra chinensis bail: An overview of Russian research and uses
in medicine. J Ethnopharmacol. 118:183–212. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ip SP, Poon MK, Wu SS, Che CT, Ng KH, Kong
YC and Ko KM: Effect of schisandrin B on hepatic glutathione
antioxidant system in mice: Protection against carbon tetrachloride
toxicity. Planta Med. 61:398–401. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Checker R, Patwardhan RS, Sharma D, Menon
J, Thoh M, Bhilwade HN, Konishi T and Sandur SK: Schisandrin B
exhibits anti-inflammatory activity through modulation of the
redox-sensitive transcription factors Nrf2 and NF-κB. Free Radic
Biol Med. 53:1421–1430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Liu Z, Sun J, Pan Q, Sun F, Yan Z
and Hu X: Schisandrin B prevents doxorubicin-induced chronic
cardiotoxicity and enhances its anticancer activity in vivo. PLoS
One. 6:e283352011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thandavarayan RA, Giridharan VV, Arumugam
S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K and Konishi T:
Schisandrin B prevents doxorubicin induced cardiac dysfunction by
modulation of DNA damage, oxidative stress and inflammation through
inhibition of MAPK/p53 signaling. PLoS One. 10:e01192142015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen P, Pang S, Yang N, Meng H, Liu J,
Zhou N, Zhang M, Xu Z, Gao W, Chen B, et al: Beneficial effects of
schisandrin B on the cardiac function in mice model of myocardial
infarction. PLoS One. 8:e794182013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chiu PY and Ko KM: Schisandrin B protects
myocardial ischemia-reperfusion injury partly by inducing Hsp25 and
Hsp70 expression in rats. Mol Cell Biochem. 266:139–144. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang W, Sun Z and Meng F: Schisandrin B
ameliorates myocardial ischemia/reperfusion injury through
attenuation of endoplasmic reticulum stress-induced apoptosis.
Inflammation. 40:1903–1911. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Jiang XL, Liu Y, Jiang DS, Zhang Y,
Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC and Li H:
Toll-interacting protein (Tollip) negatively regulates pressure
overload-induced ventricular hypertrophy in mice. Cardiovasc Res.
101:87–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, You L, Cheng Y, Hu K, Wang Z,
Cheng Y, Yang J, Yang Y and Wang G: Investigation of
pharmacokinetics, tissue distribution and excretion of schisandrin
B in rats by HPLC-MS/MS. Biomed Chromatogr. 32:2018.
|
|
19
|
Ko KM, Chen N, Leung HY, Leong EP, Poon MK
and Chiu PY: Long-term schisandrin B treatment mitigates
age-related impairments in mitochondrial antioxidant status and
functional ability in various tissues, and improves the survival of
aging C57BL/6J mice. Biofactors. 34:331–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leong PK, Chiu PY and Ko KM:
Prooxidant-induced glutathione antioxidant response in vitro and in
vivo: A comparative study between schisandrin B and curcumin. Biol
Pharm Bull. 35:464–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiu PY and Ko KM: Schisandrin B-induced
increase in cellular glutathione level and protection against
oxidant injury are mediated by the enhancement of glutathione
synthesis and regeneration in AML12 and H9c2 cells. Biofactors.
26:221–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beetz N, Rommel C, Schnick T, Neumann E,
Lother A, Monroy-Ordonez EB, Zeeb M, Preissl S, Gilsbach R,
Melchior-Becker A, et al: Ablation of biglycan attenuates cardiac
hypertrophy and fibrosis after left ventricular pressure overload.
J Mol Cell Cardiol. 101:145–155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhai M, Liu Z, Zhang B, Jing L, Li B, Li
K, Chen X, Zhang M, Yu B, Ren K, et al: Melatonin protects against
the pathological cardiac hypertrophy induced by transverse aortic
constriction through activating PGC-1beta: In vivo and in vitro
studies. J Pineal Res. 63:2017. View Article : Google Scholar
|
|
25
|
Moens AL, Takimoto E, Tocchetti CG, Chakir
K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K,
Halushka MK, et al: Reversal of cardiac hypertrophy and fibrosis
from pressure overload by tetrahydrobiopterin: Efficacy of
recoupling nitric oxide synthase as a therapeutic strategy.
Circulation. 117:2626–2636. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Urban ML, Manenti L and Vaglio A:
Fibrosis-A common pathway to organ injury and failure. N Engl J
Med. 373:95–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Q, Zhang H, Cao Y, Li Y, Sun S, Zhang
J and Zhang G: Schisandrin B attenuates CCl4-induced
liver fibrosis in rats by regulation of Nrf2-ARE and TGF-β/Smad
signaling pathways. Drug Des Devel Ther. 11:2179–2191. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang D, Liu B, Cao B, Wei F, Yu X, Li GF,
Chen H, Wei LQ and Wang PL: Synergistic protection of Schizandrin B
and Glycyrrhizic acid against bleomycin-induced pulmonary fibrosis
by inhibiting TGF-β1/Smad2 pathways and overexpression of NOX4. Int
Immunopharmacol. 48:67–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin H, Wang Z, Gu Z, Wu J, Bai X, Shao Z,
Miao J, Wang Q, Wang Q and Wang X: Schisandrin B attenuates
epidural fibrosis in postlaminectomy rats by inhibiting
proliferation and extracellular matrix production of fibroblasts.
Phytother Res. 33:107–116. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hunter JJ, Tanaka N, Rockman HA, Ross J Jr
and Chien KR: Ventricular expression of a MLC-2v-ras fusion gene
induces cardiac hypertrophy and selective diastolic dysfunction in
transgenic mice. J Biol Chem. 270:23173–23178. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cowan KJ and Storey KB: Mitogen-activated
protein kinases: New signaling pathways functioning in cellular
responses to environmental stress. J Exp Biol. 206:1107–1115. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ran J, Ma C, Xu K, Xu L, He Y, Moqbel SAA,
Hu P, Jiang L, Chen W, Bao J, et al: Schisandrin B ameliorated
chondrocytes inflammation and osteoarthritis via suppression of
NF-κB and MAPK signal pathways. Drug Des Devel Ther. 12:1195–1204.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park EJ, Chun JN, Kim SH, Kim CY, Lee HJ,
Kim HK, Park JK, Lee SW, So I and Jeon JH: Schisandrin B suppresses
TGFbeta1 signaling by inhibiting Smad2/3 and MAPK pathways. Biochem
Pharmacol. 83:378–384. 2012. View Article : Google Scholar : PubMed/NCBI
|
